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Abstract: 
 
The high affinity IgE receptor, FcεRI, plays key roles in an array of acute and chronic human 
allergic reactions including asthma, allergic rhinitis, atopic dermatitis, urticaria and anaphylaxis. 
In humans and rodents, this receptor is found at high levels on basophils and mast cells where its 
activation by IgE and multivalent antigen produces mediators and cytokines responsible for 
FcεRI-dependent acute inflammation. Mast cells can additionally contribute to sustained 
inflammatory responses by internalizing antigen bound to IgE-FcεRI complexes for processing 
to peptides and presentation to T cells. In humans, the FcεRI is also expressed, at lower density, 
on monocytes, macrophages and dendritic cells (DC) where its likely functions again include 
both signaling to mediator and cytokine production and antigen presentation. Our laboratories 
have focused on defining the earliest steps in the FcεRI signaling cascade in basophils and mast 
cells and on developing new routes to control allergic inflammation based on inhibiting these 
events. Here, we describe novel strategies to limit antigen-stimulated FcεRI signaling by: (1) 
sequestering the FcεRI-associated protein-tyrosine kinase, Lyn, that initiates FcεRI signaling; (2) 
eliminating; or (3) inactivating the protein-tyrosine kinase, Syk, that propagates FcεRI signaling; 
and (4) establishing inhibitory crosstalk between FcεRI and a co-expressed receptor, FcγRII, that 
again limits FcεRI-mediated Syk activation. These strategies may form the basis for new 
therapies for allergic inflammation. 
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Article: 
 
1. Introduction: the distribution and function of the high affinity IgE receptor, FcεRI 
 
1.1. Basophils and mast cells 
 
Mammalian basophils and mast cells express high levels of the tetrameric (αβγ2) high affinity 
IgE receptor, FcεRI (Fig. 1) implicated in an array of acute and chronic allergic reactions 
including asthma, allergic rhinitis, atopic dermatitis, urticaria and anaphylaxis. IgE-mediated 
allergic inflammation is stimulated by a two-step process in which basophils and mast cells are 
first primed by the binding of allergen-specific IgE to the α subunit of the FcεRI and then 
activated by allergen that crosslinks adjacent IgE-FcεRI complexes. Crosslinking FcεRI in the 
cell membrane activates two cytoplasmic tyrosine kinases, Lyn and Syk, that in turn 
phosphorylate and activate enzymes (PLCγ isoforms, PI 3-kinase isoforms, PKC isoforms, Akt, 
BTK, MEK, ERK1/ERK2, JNK and others), adaptors (Cbl, Grb2, SLP-76, LAT and others) and 
GTP exchange factors/GTPases (Ras, Rho, Vav, Sos and others) and induce the mobilization of 
stored and extracellular Ca2+. These and other biochemical and ionic events lead within seconds 
to minutes to the secretion of inflammatory mediators such as histamine that induce airway 
constriction, mucous production and other acute allergic symptoms. They also rapidly induce 
actin polymerization, membrane ruffling, the assembly of actin plaques at sites of cell-substrate 
interaction and the upregulation of VLA-4-mediated adhesion. These responses are likely to be 
involved in basophil recruitment from blood to inflamed tissues and in the migration of both 
basophils and mast cells within and between tissues. Several hours after FcεRI crosslinking, 
basophils and mast cells additionally begin the production of cytokines, including IL-4 and IL-
13, strongly implicated in the activation of the TH2 (pro-inflammatory) subset of T cells and in 
the stimulation of B cells to produce more IgE. 
 
 
Fig. 1. The structure and distribution of human FcεRI. The left panel shows the heterotetrameric (αβγ2) FcεRI found 
primarily on basophils and mast cells. The heterotrimeric variant of the FcεRI expressed mainly on antigen-
presenting cells is shown in the right panel. The figure is modified from Kinet (1999). 
 
Fig. 2 shows a sampling of the FcεRI-coupled biochemical pathways and physiological 
responses of basophils and mast cells. All of the events depicted have been reported in rodent 
mast cells. Many have been extended to human peripheral blood basophils and/or cord blood-
derived mast cells. The antigen-induced membrane ruffling response of human basophils is 
demonstrated here for the first time in Fig. 3. These and other FcεRI-mediated signaling 
responses have recently been described in chapters contributed by many groups, including our 
own, to books edited by Hamawy (1997) and Razin and Rivera (1999). 
 
 
Fig. 2. An overview of FcεRI signaling. Boxes outside the “cell” list the principal physiological responses induced 
by FcεRI crosslinking in basophils and mast cells. A subset of the biochemical and ionic events linking FcεRI 
crosslinking to these physiological responses are depicted inside the “cell”. 
 
Mecheri and colleagues have reported that IgE-primed mast cells can function additionally as 
antigen-presenting cells (APC), focusing and internalizing allergen into vesicular compartments 
for processing to small peptides that form complexes with MHC class II and can be re-expressed 
on the cell surface both by constitutive vesicular trafficking and by a more abrupt delivery 
induced by a second round of antigen-induced FcεRI crosslinking Raposo et al., 1997, Tkaczyk 
et al., 1999. This newly recognized physiological function of the mast cell FcεRI, also shown 
in Fig. 2, implicates the mast cell in T cell activation not only via cytokine production but also 
through antigen presentation. 
 
 
 
Fig. 3. Human basophil ultrastructure. IgE-primed human basophils were incubated without (A) or with (B) 
multivalent antigen for 5 min, then fixed and processed for TEM. The resting cell has a densely granulated 
cytoplasm and a fairly rounded shape. The activated cell has abundant surface ruffles and shows evidence of 
intracytoplasmic granule fusion. Bar=1 μM. 
1.2. Of mouse and man 
 
In rodents, only basophils and mast cells express FcεRI and it occurs only in the tetrameric 
αβγ2 form. In contrast, humans express a trimeric variant of the FcεRI, lacking the α subunit, in 
monocytes, macrophages, a range of dendritic cells (DC) including those in blood, lung and 
dermis, epidermal Langerhans cells and DC differentiated from cord blood (Fig. 1). FcεRI 
expression levels on these various APC are typically between<1–10% of the levels measured on 
basophils and mast cells, with higher levels being characteristically found on cells from donors 
with higher levels of circulating IgE and with various allergic diseases. The consequences for 
IgE binding affinity of expressing FcεRI in the αγ2 rather than the αβγ2form are not substantial. 
However, there is evidence that crosslinking the αγ2 FcεRI isoform activates Syk, PLCγ and PI 
3-kinase and mobilizes Ca2+, all properties shared with the αβγ2 FcεRI. Importantly, there is 
growing evidence that the αγ2 FcεRI on monocytes, macrophages and DC are critically involved 
in allergen-focusing, internalization and processing as described above for mast cells. There is 
also limited evidence linking atopic dermatitis to the expression of αβγ2 rather than αγ2 FcεRI in 
Langerhans cells and there are reports of low levels of expression of the FcεRI (αβγ2 in some 
reports; αγ2 in others) on human eosinophils and platelets. Thus, in man, the FcεRI may promote 
allergic inflammation via effects on a range of hematopoietic cells in addition to basophils and 
mast cells. Work in this area was recently reviewed by Bieber (1996), Stingl and Maurer 
(1997) and Kinet (1999). 
 
2. Therapeutic targets for allergic diseases in the human FcεRI signaling pathway 
 
2.1. Rationale 
 
Many investigators have sought inhibitors of human FcεRI signaling on the premise that 
inhibiting basophil and mast cell degranulation should block the symptoms, if not necessarily the 
underlying immunological cause, of IgE-mediated allergic inflammation. As described above, 
we now know that FcεRI-positive basophils, mast cells and DC can additionally generate pro-
inflammatory cytokines and present antigen to T cells. These new data suggest that reliable 
blockade of FcεRI signaling is likely not only to relieve allergic symptoms but also to arrest the 
cycle of immunological events associated with disease progression. 
 
Until recently, studies of human FcεRI signaling were quite difficult because FcεRI-positive 
cells were simply not available in sufficient numbers. Recent advances have improved the yield 
and speed of basophil isolation from human blood Bochner et al., 1997, Kepley et al., 1998a and 
have provided protocols to differentiate basophils and mast cells from cord blood Saito et al., 
1995, Kepley et al., 1998b. Human DC and monocytes are available from blood and 
macrophages can be obtained from bronchial alveolar lavage fluid. At least for human basophils, 
the antigen-activated FcεRI signaling pathway is comfortingly similar, although not identical, to 
the well-characterized rodent pathway (Kepley et al., 1998a). It is finally possible to search for 
new therapeutic targets for allergic diseases in the human FcεR1 signaling pathway. 
 
2.2. Strategies 
 
Fig. 4 shows our current understanding of the sequence of events linking FcεRI crosslinking to 
Syk activation and downstream signaling. The earliest known FcεRI-induced response is the 
Lyn-mediated phosphorylation of tyrosines located in the immunoreceptor tyrosine-based 
activation motifs (ITAMs) of the β and γ subunits of the tetrameric (αβγ2) FcεRI. The FcεRI γ 
subunit has a typical ITAM consisting of two YXXL sequences separated by approximately 10 
amino acids. The FcεRI β ITAM has two YXXL motifs and a third tyrosine in the intervening 
sequence. Work in the Metzger laboratory at NIH has emphasized the role of Lyn's interaction 
with FcεRI β subunits in the process of β and γ subunit phosphorylation (reviewed in Metzger, 
1999). Brugge and others have shown the critical role of the dually phosphorylated γ subunit 
ITAM in the recruitment and activation of Syk (Rivera and Brugge, 1995). Linking these studies, 
our recent work, described below, has identified Lyn dissociation from fully phosphorylated 
FcεRI as a new regulatory event required for Syk-phospho-ITAM interaction and signal 
propagation (Ortega et al., 1999). 
 
 
Fig. 4. Modeling FcεRI signal initiation. FcεRI signaling is initiated by the Lyn-mediated tyrosine phosphorylation 
of ITAMs in the β and γ subunits of the heterotrimeric (αβγ2) FcεRI. Subsequent Lyn displacement reveals phospho-
ITAM binding sites for Syk recruitment and activation. FcεRI signaling can be antagonized by phosphatases 
presented by co-crosslinked FcγRII. Therapeutic interventions proposed here to block these initiating events include 
treatments that: (1) block IgE-receptor interaction; (2) prevent the dissociation of Lyn from phosphorylated receptor 
subunits; (3) impair either the expression or activation of Syk; and (4) recruit FcγRII and its cargo of phosphatases 
to the FcεRI signaling complex. 
 
The most direct way to block FcεRI signaling is to prevent IgE binding to the receptor, thereby 
preventing FcεRI crosslinking and signal initiation. The work of P. Jardieu and colleagues at 
Genentech, with laboratory and clinical collaborators at many institutions, has demonstrated 
remarkable new results in this area with a recombinant humanized anti-IgE Ab, E25. RhumAb 
E25 binds circulating IgE at the site that normally interacts with FcεRI α, forming immune 
complexes that cannot bind to FcεRI. In humans, biweekly subcutaneous administration of E25 
causes a substantial reduction in allergic rhinitic and asthma symptoms. Symptomatic 
improvement is accompanied by dramatically reduced serum IgE levels and basophil FcεRI 
expression levels. To date, almost no complications associated with drug treatment or withdrawal 
have been encountered (Heusser and Jardieu, 1997, Saini et al., 1999; see also the paper by P. 
Jardieu in this volume). Thus, current concern about this treatment focuses largely on the 
expense and inconvenience of bimonthly injections of recombinant protein. The Genentech study 
establishes a central role for IgE in human allergic inflammation. It focuses attention on the 
FcεRI signaling pathway as a target for the development of new therapeutics. 
 
The second obvious way to block FcεRI signaling is to prevent the propagation of signals from 
crosslinked receptors. Targets immediately downstream of FcεRI crosslinking include Lyn 
activation, the dissociation of Lyn from phosphorylated receptor subunits, and the recruitment 
and activation of Syk. Here we describe strategies that may ultimately generate new therapies for 
allergic inflammation based on the specific inhibition of the earliest events in the FcεRI-
mediated signaling cascade. 
 
2.3. “Lyn-sequestering, signal-curtailing” FcεRI dimers block mast cell activation 
 
Collaborative studies between our laboratories in New Mexico and in Mexico City of the 
differences in signaling competence between three anti-FcεRI α mAbs originally produced in the 
Pecht laboratory at the Weizmann Institute (Ortega et al., 1988) led to our first model for rational 
allergy and asthma therapy through the blockade of FcεRI signal propagation. These mAbs bind 
competitively with each other and with IgE to the FcεRI of RBL-2H3 rat tumor mast 
cells (Ortega et al., 1988). Nevertheless, mAb H10 is a poor secretagogue in comparison with 
mAbs F4 and J17. We demonstrated that the mAb H10-FcεRI interaction also induces very little 
Ins(1,4,5)P3 production, Ca2+ mobilization or cytoskeletal reorganization in comparison with 
multivalent Ag or with anti-FcεRI mAbs, F4 and J17. Little or no internalization of mAb H10-
FcεRI complexes was detectable on RBL-2H3 cells (Ortega et al., 1999). In contrast, FcεRI 
complexes with multivalent crosslinkers redistribute to coated pits and are cleared rapidly from 
the mast cell surface. 
 
Although mAb H10 was severely signaling-impaired, H10-induced Lyn phosphorylation, the 
first known step in FcεRI signaling, was apparently normal. Furthermore, H10-receptor 
complexes supported more FcεRI β and γ subunit phosphorylation than signaling-competent 
crosslinkers in anti-phosphotyrosine immune complex kinase assays. However, mAb H10 was a 
poor Syk activator, suggesting that FcεRI signaling proceeds efficiently from Lyn to receptor 
subunits but inefficiently from subunit phosphorylation to Syk when FcεRI crosslinking is 
induced with mAb H10. 
 
Further studies showed that Lyn immune complexes from H10-treated cells contained substantial 
amounts of phosphorylated FcεRI β and γ subunit. In contrast, only very small amounts of β and 
γ subunits could be found associated with Lyn in complexes from cells treated either with 
multivalent ligand or with signaling-competent anti-FcεRI mAbs. We also found that the 
principal phospho-β species induced by mAb H10 in intact cells was a less completely 
phosphorylated isoform than the principal phospho-β species in antigen-treated cells. It was 
suggested that the failure of Lyn dissociation and signal propagation in mAb H10-treated cells 
may reflect differences in conformation or orientation between FcεRI dimers induced by mAb 
H10 and FcεRI dimers and multimers induced by signaling-competent crosslinkers. Supporting 
this hypothesis, multivalent complexes of mAb H10 with F(ab)′2 rabbit anti-mouse IgG activate a 
normal sequence of Lyn recruitment and displacement and of Syk activation, presumably 
because a signaling-competent configuration of crosslinked receptors had been achieved between 
co-crosslinked dimers. 
 
From these and other data, we proposed Lyn dissociation from optimally oriented and 
phosphorylated FcεRI β subunits as a previously unknown rate-limiting step required for Syk 
activation and signal propagation (Ortega et al., 1999). We speculated that receptor orientation 
and subunit phosphorylation may be key regulators of signal initiation not only for FcεR1 but 
also for other key immune system receptors. Supporting this, there is now evidence in T cells 
linking the poor signaling activity of some altered peptide ligands (APLs) to incomplete 
phosphorylation of the TCR ζ subunit (Kersh et al., 1998) and independent evidence linking the 
poor signaling activity of some cytokines to the induction of cytokine receptor dimers with 
unfavorable orientations (reviewed in Jiang and Hunter, 1998). 
 
Importantly, Wofsy and colleagues have established that Lyn is rate-limiting for FcεRI 
signaling Wofsy et al., 1997, Wofsy et al., 1999. Based on their analyses, we proposed further 
that crosslinkers like mAb H10, that sequester Lyn through the formation of stable complexes 
between Lyn and receptor dimers, should be strong inhibitors of allergen-induced FcεRI 
signaling. One current goal is to generate and test “Lyn-sequestering, signal-curtailing” 
crosslinkers of the human FcεRI as novel therapeutic agents for allergic inflammation. 
 
The micrographs in Fig. 5 provide direct support for a model in which productive signaling 
involves a “kiss-and-run” interaction of Lyn with crosslinked receptor and in which reagents like 
mAb H10 that bring crosslinked FcεRI into a stably Lyn-bound conformation (“kiss-and-stick”) 
will inhibit Syk recruitment and signal propagation. In these images, RBL-2H3 cells were 
activated with multivalent antigen (1 μg/ml DNP-BSA) for 2 min or with 70 nM mAb H10 for 5 
min, times shown previously to give the strongest peaks, respectively, of antigen- and mAb-
induced tyrosine phosphorylation (Ortega et al., 1999). Membrane sheets were prepared by a 
modification of the method of Sanan and Anderson (1991) and labeled with colloidal gold 
particles conjugated to Abs specific for FcεRI β (the 3 nm particles) or for Lyn (the 5 nm 
particles). In the absence of crosslinking, FcεRI β and Lyn appeared to be loosely co-localized 
with each other but not with clathrin lattices (Fig. 5A). Following 2 min of crosslinking with 
DNP-BSA, most of the FcεRI β is in clusters (Fig. 5B). Many of the smaller FcεRI β clusters 
also contain Lyn (circles). The larger FcεRI β clusters (boxed) typically contain little or no Lyn. 
These clusters are, however, surrounded by Lyn-containing membrane as might occur if receptor 
and kinase had first interacted and then segregated in the plane of the membrane. One of the two 
large clusters of FcεRI β in Fig. 5B is closely associated with two clathrin-coated pits. In 
contrast, FcεRI β is concentrated in small clusters that include Lyn and show no interaction with 
clathrin-coated membrane when crosslinking is induced by the signal-curtailing mAb H10 (Fig. 
5C). These typical images are compatible with our biochemical evidence (above): that mAb H10 
induces the formation of stable complexes of Lyn with receptor whereas, Lyn-receptor 
complexes are transient in cells treated with signaling-competent antigen. The clear exclusion of 
mAb H10-receptor complexes from clathrin-coated membrane supports other evidence that H10-
like therapeutics should have a long half-life on the cell surface. 
 
2.4. Syk deficiency in “non-releaser” basophils 
 
Studies of the failure of FcεRI-mediated secretion and cytokine synthesis that occurred in 
basophils from five of 40 healthy non-allergic donors (and has previously been observed in 10–
20% of non-allergic donors screened by other groups; see for example the chapter by D. 
MacGlashan in Razin and Rivera, 1999) led to a second model for rational therapy based on the 
blockade of FcεRI signal initiation (Kepley et al., 1999a). “Non-releaser” basophils express 
normal levels of FcεRI and show normal secretion and cytokine synthesis responses to 
Ca2+ ionophore, phorbol ester and formyl peptide, all stimuli that bypass the FcεRI. Their 
signaling and secretory machinery thus seems intact. The cells are morphologically normal, 
although they fail to ruffle in response to FcεRI crosslinking. Further analysis showed that Syk 
protein is absent from the basophils of all five donors. Although basophils lack Syk protein, B 
cells, eosinophils and neutrophils from non-releaser donors express normal levels of this kinase. 
Furthermore, Syk mRNA has been detected at variable levels in highly purified basophils from 
all five non-releaser donors. Basophils from one non-releaser converted to the releaser 
phenotype, accompanied by Syk protein expression, and reverted back to the non-releaser 
phenotype in the 6-month course of our studies. Basophils from all five non-releasers expressed 
Syk and showed modest degranulation after incubation for 4 days in medium with IL-3. These 
data suggest that basophil Syk expression is manipulatable both in vivo and in vitro. 
 
These results show a clear relationship between the lineage-specific lack of Syk expression and 
the lack of FcεRI-mediated signaling activity in human non-releaser basophils. Our challenge is 
to determine the mechanism by which basophils from some donors selectively suppress Syk 
expression and to apply this knowledge to suppress Syk expression in the basophils and mast 
cells of allergy sufferers. Our current effort is focused on the product of the Cbl proto-oncogene. 
Cbl has been identified as a binding partner and negative regulator of Syk that reduces both Syk 
phosphorylation and Syk levels (Lupher et al., 1999). Remarkably, the RING finger domain of 
Cbl has ubiquitin-protein ligase activity (Joazeiro et al., 1991). Thus Cbl overexpression or 
excessive catalytic activity could promote the degradation of Syk protein in non-releaser 
basophils. 
 
 
 
 
Fig. 5. Observing Lyn-receptor interaction induced by signaling-competent and signal-curtailing FcεRI crosslinkers. 
Membrane sheets were produced from the upper surface of variously activated RBL-2H3 cells by a modification of 
the method of Sanan and Anderson (1991). The inner membrane was fixed lightly and labeled with gold-conjugated 
antibody specific for FcεRI β subunits (the 3 nm gold particles) and for Lyn (the 5 nm gold particles). The three 
panels show the distributions of FcεRI β and Lyn on the inner membranes of unstimulated cells (A), of cells 
incubated for 2 min with multivalent antigen (B), and of cells incubated for 5 min with mAb H10, respectively. In 
unstimulated cells (A), FcεRI β and Lyn appear to be loosely associated in dispersed clusters over the inner cell 
membrane (circles). Neither marker co-localizes with clathrin lattices. In antigen-stimulated cells (B), FcεRI β 
occurs in small clusters with Lyn (circles) and also in larger clusters that largely exclude Lyn (boxes). A pair of 
coated vesicles appears to be budding from membrane adjacent to one of these larger clusters. In mAb H10-
stimulated cells (C), FcεRI β is concentrated in small clusters that typically include Lyn and do not associate with 
coated pits (circles). Bar=0.1 μM. 
 
2.5. Selective inhibition of FcεRI-mediated Syk activation 
 
Collaborative studies between our laboratories in New Mexico and the Geahlen laboratory at 
Purdue University were the first to localize Syk to the FcεRI signaling complex of RBL-2H3 
mast cells (Hutchcroft et al., 1992) and to identify the novel stilbene derivative, piceatannol, as a 
Syk-selective inhibitor capable of blocking all known signaling responses downstream of Syk in 
both RBL-2H3 cells (Oliver et al., 1994) and human basophils (Kepley et al., 1998a). Although 
Syk expression is limited to hematopoietic cells, this kinase is nevertheless a key component of 
the signaling pathways activated through both antigen and adhesion receptors on B cells, NK 
cells, monocytes, macrophages and platelets. Thus the therapeutic potential of piceatannol for 
allergic inflammation is not high without additional targeting to limit its interaction to only 
basophils and mast cells. It may be possible to provide this targeting specificity by conjugating 
piceatannol to humanized Abs or ligands for basophil and mast cell-specific co-receptors that 
could internalize the drug by receptor-mediated endocytosis. Ligands for co-receptors with C-
terminal immunoreceptor tyrosine-based inhibitory motifs (ITIMs), typically consisting of 13 
amino acid sequences including a single YXXL motif, are particularly attractive candidates since 
occupying these receptors does not induce degranulation and can in fact reduce degranulation 
induced by FcεRI crosslinking (see below). Obvious targets include the putative human analog 
of MAFA, a C-type lectin found primarily on rat mast cells (Guthman et al., 1995) and HM18, 
recently identified as the human analog of gp49B1 found primarily on mouse mast cells (see the 
chapter by H. Katz in Razin and Rivera, 1999). 
 
The search for Syk inhibitors that target basophils and mast cells may be advanced by 
additionally learning more about the Syk-phospho-ITAM interaction that activates Syk. Moriya 
et al. (1997) demonstrated that the novel acridone-related compound, ER-27319, inhibits Syk 
tyrosine phosphorylation and downstream signaling in RBL-2H3 mast cells not by directly 
inactivating Syk but by blocking its association with the FcεRI γ subunit phospho-ITAM, a 
prerequisite for Syk activation in vivo. Remarkably, Syk activation induced by its binding to the 
Ig β ITAM of the B cell receptor is not inhibited by ER-27319 despite the substantial structural 
similarity that exists between the ITAMs of different receptors. Of course, ER-27319 can be 
expected to inhibit signaling through other receptors that use the FcεRI γ subunit, including 
FcRγI, FcγRIII, some T cell receptor isoforms and the platelet collagen receptor Daeron, 
1997, Watson and Gibbins, 1998. Nevertheless, ER-27319 may serve as a parent compound for 
the development of inhibitors of human mast cell responses that specifically inhibit interactions 
between Syk and the FcεRI γ subunit while sparing Syk-dependent functions of other critical 
immune cells. 
 
2.6. FcεRI/FcγRII co-crosslinking blocks FcεRI-mediated basophil and mast cell activation 
 
Studies of crosstalk between FcγRII and FcεRI on human basophils have potential to provide an 
independent method to block FcεRI-mediated signal propagation in human cells. We (Kepley et 
al., 1999b) confirmed published evidence that human basophils and mast cells express only the 
low affinity IgG receptor, FcγRII and not FcγRI or FcγRIII (Anselmino et al., 1989). In 
collaboration with P. Morel at the University of Pittsburgh, we found that the principal FcγRII 
species in peripheral blood basophils and cord blood-derived mast cells is the ITIM-containing 
FcγRIIB isoform. Basophils also contain mRNA for the ITAM-containing FcγRIIA isoform but 
not for FcγRIIC. Importantly, we demonstrated that FcεRI-mediated secretion, IL-4 production, 
Ca2+mobilization and Syk phosphorylation are all significantly reduced when FcεRI and FcγRII 
are primed with anti-DNP IgE and anti-DNP IgG, respectively, and co-crosslinked with the same 
antigen. 
 
These results resembled published data from B cells, where co-crosslinking the BCR to FcγRIIB 
inhibits BCR-mediated cell activation (reviewed in Cambier, 1997, Daeron, 1997). In B cells, the 
mechanism of inhibition most likely involves the Lyn-mediated tyrosine phosphorylation of the 
ITIM sequence found in the FcγRIIB cytoplasmic tail, creating phosphotyrosine binding sites for 
the SH2 domain-containing phospholipase, phosphatidylinositol 5-phosphatase (SHIP) and for 
the SH2 domain-containing protein tyrosine phosphatases, SHP-1 and SHP-2. Following this 
lead, we showed that human basophils express SHP-1, SHP-2 and SHIP; demonstrated that 
phosphorylated FcγRIIB ITIM peptides recruit SHP-1 from basophil lysates; and finally, 
established that SHP-1 translocates to the basophil membrane in response to FcγRII crosslinking. 
These data support the hypothesis that negative signaling from FcγRII to the FcεR1 of human 
basophils occurs at least in part by the recruitment of SHP-1 to the FcγRIIB ITIM, positioning it 
to block or reverse the phosphorylation and activation of Syk needed to couple FcεR1 
crosslinking to downstream responses. It remains possible that the less abundant SHIP also 
contributes to the inhibition of FcεR1 signaling by co-crosslinked FcγRII in human basophils and 
that more sentitive detection methods will reveal its involvement. 
 
The therapeutic potential of these studies may already have been applied in clinical practice. 
Physicians have used immunotherapy, the injection of increasing doses of substances that induce 
allergic responses in patients with severe allergies, for most of the 20th century. Successful 
immunotherapy, defined by reduced responsiveness to particular antigens, has been linked to 
increased levels of allergen-specific IgG, sometimes accompanied by increased levels of IgE 
specific for the same allergen. It is generally assumed that the clinical improvement results from 
the neutralization and clearance of circulating allergen by the newly synthesized IgG. Extending 
a suggestion made earlier by Daeron (1997), we hypothesize that the efficacy of immunotherapy 
in some allergy patients may result additionally from allergen-mediated FcγRII/FcεRI co-
crosslinking on basophils and mast cells, resulting in the FcγRIIB-mediated recruitment of 
signal-terminating phosphatases to the FcεRI signaling complex in vivo. This co-crosslinking 
could occur in at least three ways. The first is by the binding of allergen to dually (IgG plus IgE)-
primed basophils and mast cells, just as in our in vitro model. However, FcγRII is a low affinity 
receptor that prefers to bind IgG aggregates (hence our considerable search for an anti-DNP IgG 
for basophil priming). Thus, a second, and perhaps more likely, route to FcγRII/FcεRI co-
crosslinking in vivo would involve the simultaneous binding of allergen-IgG complexes to IgE-
primed FcεRI and to unprimed FcγRII on basophils and mast cells. Co-crosslinking could also 
occur if the circulating immune complexes contained IgE as well as IgG and allergen and the 
complexes bound simultaneously to unprimed FcγRII and to unprimed FcεRI on basophils and 
mast cells. In all cases, individuals with little or no basophil and mast cell FcγRIIB, and thus 
little ability to draw phosphatases into the FcεRI signaling complex, would not be expected to 
benefit from immunotherapy. Thus it may be possible in the future to predict the success or 
failure of immunotherapy based on the heterogeneity in FcγRII isoform expression between 
individuals. 
 
3. Summary 
 
The success of the Genentech-sponsored studies of anti-IgE immunotherapy, that have so far 
provided symptomatic relief to over 90% of patients enrolled in trials, strongly supports the use 
of strategies to block human FcεRI signaling as a general approach to limit or even prevent the 
symptoms of allergic inflammation (see the review by P. Jardieu in this volume). Because FcεRI-
positive cells are increasingly implicated in the cycle of immunological events (cytokine 
production, cell migration, antigen presentation) responsible for disease progression, it is likely 
that inhibiting FcεRI signaling will also help to correct the immunological imbalance that 
maintains the allergic phenotype. 
 
This paper summarizes four alternative strategies to inhibit early events regulating FcεRI signal 
propagation. The strategies we describe have potential to complement other new therapies based 
on the neutralization of IgE or of cytokines as well as established therapies with antihistamines 
and steroids. 
 
In the first study, FcεR1 crosslinkers that activate Lyn but fail to release Lyn from 
phosphorylated FcεR1 subunits, a prerequisite for Syk recruitment and signal propagation were 
used to prevent FcεR1 signal propagation (Ortega et al., 1999). These reagents are so far 
available only for the rodent FcεR1. Analogous “Lyn-sequestering, signal-curtailing” ligands 
could be effective inhibitors of Syk activation and signal propagation through the human FcεRI. 
 
The second study showed that the 10% or so of “non-releaser” human donors lack basophil Syk 
protein expression even though Syk levels are normal in co-purified B cells (Kepley et al., 
1999a). Understanding mechanisms regulating this lineage-specific Syk expression may yield 
strategies to selectively inhibit its expression in FcεRI-positive cells from asthmatics. 
 
The third approach was by the pharmacological inhibition of Syk. Our work has identified 
piceatannol as a Syk-selective drug that still requires further engineering, most obviously by its 
conjugation to ligands for mast cell specific co-receptors, for uptake specifically into basophils 
and mast cells (Oliver et al., 1994). Complementary work by the group at Esai in Japan, in 
collaboration with the J. Rivera laboratory at NIH, has identified ER-27319 as a drug that 
inhibits the association of Syk with the phospho-ITAMs of FcεR1γ, but not of other members of 
the multichain immunoregulatory receptors (Moriya et al., 1997). Because the FcεR1 γ subunit is 
a component of several immune receptors, ER-27319 also requires further engineering for 
targeting specifically to basophils and mast cells. Nevertheless, this evidence that Syk may 
interact differently with different phospho-ITAMs encourages the continued search for 
therapeutic agents that inactivate Syk in human basophils and mast cells while sparing other Syk-
dependent cells. 
 
The final study shows that human FcεRI signaling is inhibited in vitro by phosphatases presented 
to FcεRI by co-crosslinked FcγRII (Kepley et al., 1999b). In this case the therapy may have 
preceded the science. Immunotherapy, practiced in the clinic since the mid-1930's, may work in 
part by stimulating the production of allergen-specific IgG in patients who are already producing 
allergen-specific IgE. We hypothesize that the simultaneous interactions of these IgE and IgE 
antibodies with common allergen but distinct receptors on basophils and mast cells may co-
crosslink FcεRI and FcγRII, blocking FcεRI signal propagation in vivo through the recruitment 
of FcγRII-associated phosphatases to the FcεRI signaling complex and contributing to the 
reduction of allergy symptoms. Studies are in progress to explore the heterogeneity of FcγRII 
isoform expression between individuals. We speculate that only patients expressing relatively 
high levels of the ITIM-containing FcγRIIB isoform in their basophils and mast cells will show a 
good response to immunotherapy. 
 
Fig. 2 shows many other potential targets for inhibitors of FcεRI-mediated signaling. We expect 
that the further refinement of strategies to block human FcεRI signal initiation or propagation 
through the heterotetrameric FcεRI of basophils and mast cells and the heterotrimeric FcεRI of 
antigen-presenting and other cells will form the basis of other new and useful therapies for 
allergic inflammation. 
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